

# Stephen R, Yant

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4523581/publications.pdf>

Version: 2024-02-01

38  
papers

4,756  
citations

172386  
29  
h-index

345118  
36  
g-index

38  
all docs

38  
docs citations

38  
times ranked

4835  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Long-acting capsid inhibitor protects macaques from repeat SHIV challenges. <i>Nature</i> , 2022, 601, 612-616.  | 13.7 | 14        |
| 2  | Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence <i>In Vitro</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0203821.                             | 1.4  | 2         |
| 3  | Simulating HIV Breakthrough and Resistance Development During Variable Adherence to Antiretroviral Treatment. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 369-377.               | 0.9  | 8         |
| 4  | Clinical targeting of HIV capsid protein with a long-acting small molecule. <i>Nature</i> , 2020, 584, 614-618.  | 13.7 | 192       |
| 5  | A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model. <i>Nature Medicine</i> , 2019, 25, 1377-1384.  | 15.2 | 104       |
| 6  | TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .                                    | 1.4  | 47        |
| 7  | Rapid <i>In Vitro</i> Evaluation of Antiretroviral Barrier to Resistance at Therapeutic Drug Levels. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 1237-1247.  | 0.5  | 3         |
| 8  | Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 7086-7097. | 1.4  | 215       |
| 9  | Structural Determinants of Sleeping Beauty Transposase Activity. <i>Molecular Therapy</i> , 2016, 24, 1369-1377.   | 3.7  | 7         |
| 10 | Intracellular Activation of Tenofovir Alafenamide and the Effect of Viral and Host Protease Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 316-322.                                      | 1.4  | 59        |
| 11 | Metabolism and Antiretroviral Activity of Tenofovir Alafenamide in CD4 <sup>+</sup> T-Cells and Macrophages from Demographically Diverse Donors. <i>Antiviral Therapy</i> , 2014, 19, 669-677.                 | 0.6  | 37        |
| 12 | Tenofovir Alafenamide is Not a Substrate for Renal Organic Anion Transporters (Oats) and Does Not Exhibit Oat-Dependent Cytotoxicity. <i>Antiviral Therapy</i> , 2014, 19, 687-692.                            | 0.6  | 87        |
| 13 | Quantitative microscopy of functional HIV post-entry complexes reveals association of replication with the viral capsid. <i>ELife</i> , 2014, 3, e04114.   | 2.8  | 146       |
| 14 | Evaluation of the Effect of Cobicistat on the <i>In Vitro</i> Renal Transport and Cytotoxicity Potential of Tenofovir. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4982-4989.                     | 1.4  | 41        |
| 15 | Non-Catalytic Site HIV-1 Integrase Inhibitors Disrupt Core Maturation and Induce a Reverse Transcription Block in Target Cells. <i>PLoS ONE</i> , 2013, 8, e74163.   | 1.1  | 118       |
| 16 | Somatic Integration From an Adenoviral Hybrid Vector into a Hot Spot in Mouse Liver Results in Persistent Transgene Expression Levels <i>In Vivo</i> . <i>Molecular Therapy</i> , 2007, 15, 146-156.           | 3.7  | 41        |
| 17 | Correction of DNA Protein Kinase Deficiency by Spliceosome-mediated RNA Trans-splicing and Sleeping Beauty Transposon Delivery. <i>Molecular Therapy</i> , 2007, 15, 1273-1279.                                | 3.7  | 24        |
| 18 | A Two-hybrid Screen Identifies Cathepsins B and L as Uncoating Factors for Adeno-associated Virus 2 and 8. <i>Molecular Therapy</i> , 2007, 15, 330-339.   | 3.7  | 74        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Site-directed transposon integration in human cells. <i>Nucleic Acids Research</i> , 2007, 35, e50-e50.   | 6.5 | 129       |
| 20 | Cis-Acting Gene Regulatory Activities in the Terminal Regions of Sleeping Beauty DNA Transposon-Based Vectors. <i>Human Gene Therapy</i> , 2007, 18, 1193-1204.   | 1.4 | 39        |
| 21 | Postintegrative Gene Silencing within the Sleeping Beauty Transposition System. <i>Molecular and Cellular Biology</i> , 2007, 27, 8824-8833.  | 1.1 | 66        |
| 22 | Sarcoma Derived from Cultured Mesenchymal Stem Cells. <i>Stem Cells</i> , 2007, 25, 371-379.  | 1.4 | 601       |
| 23 | Host factors that impact the biodistribution and persistence of multipotent adult progenitor cells. <i>Blood</i> , 2006, 107, 4182-4188.  | 0.6 | 75        |
| 24 | The 37/67-Kilodalton Laminin Receptor Is a Receptor for Adeno-Associated Virus Serotypes 8, 2, 3, and 9. <i>Journal of Virology</i> , 2006, 80, 9831-9836.  | 1.5 | 356       |
| 25 | Osteosarcoma Derived from Cultured Mesenchymal Stem Cells.. <i>Blood</i> , 2006, 108, 2554-2554.  | 0.6 | 21        |
| 26 | Real-Time in Vivo Imaging of Stem Cells Following Transgenesis by Transposition. <i>Molecular Therapy</i> , 2005, 12, 42-48.  | 3.7 | 36        |
| 27 | High-Resolution Genome-Wide Mapping of Transposon Integration in Mammals. <i>Molecular and Cellular Biology</i> , 2005, 25, 2085-2094.  | 1.1 | 298       |
| 28 | Mesenchymal Cancer Cells Can Arise from Ex Vivo Modified Mesenchymal Stem Cells.. <i>Blood</i> , 2005, 106, 4326-4326.  | 0.6 | 0         |
| 29 | Mutational Analysis of the N-Terminal DNA-Binding Domain of Sleeping Beauty Transposase: Critical Residues for DNA Binding and Hyperactivity in Mammalian Cells. <i>Molecular and Cellular Biology</i> , 2004, 24, 9239-9247. | 1.1 | 142       |
| 30 | Real-Time In Vivo Biodistribution of Multipotent Adult Progenitor Cells (MAPC): Role of the Immune System in MAPC Resistance in Non-Transplanted and Bone Marrow Transplanted Mice.. <i>Blood</i> , 2004, 104, 507-507.       | 0.6 | 0         |
| 31 | Helper-Independent sleeping beauty Transposon-Transposase vectors for efficient nonviral gene delivery and persistent gene expression in vivo. <i>Molecular Therapy</i> , 2003, 8, 654-665.                                   | 3.7 | 138       |
| 32 | Nonhomologous-End-Joining Factors Regulate DNA Repair Fidelity during Sleeping Beauty Element Transposition in Mammalian Cells. <i>Molecular and Cellular Biology</i> , 2003, 23, 8505-8518.                                  | 1.1 | 79        |
| 33 | In Vivo Correction of Murine Tyrosinemia Type I by DNA-Mediated Transposition. <i>Molecular Therapy</i> , 2002, 6, 759-769.   | 3.7 | 137       |
| 34 | Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo. <i>Nature Biotechnology</i> , 2002, 20, 999-1005.   | 9.4 | 184       |
| 35 | Linear DNAs Concatemerize in Vivo and Result in Sustained Transgene Expression in Mouse Liver. <i>Molecular Therapy</i> , 2001, 3, 403-410.   | 3.7 | 179       |
| 36 | Extrachromosomal Recombinant Adeno-Associated Virus Vector Genomes Are Primarily Responsible for Stable Liver Transduction In Vivo. <i>Journal of Virology</i> , 2001, 75, 6969-6976.   | 1.5 | 417       |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. <i>Nature Genetics</i> , 2000, 25, 35-41.   | 9.4 | 491       |
| 38 | High affinity YY1 binding motifs: identification of two core types (ACAT and CCAT) and distribution of potential binding sites within the human $\beta^2$ globin cluster. <i>Nucleic Acids Research</i> , 1995, 23, 4353-4362. | 6.5 | 149       |